Prevention of proliferative vitreoretinopathy (PVR) continues to be a challenge for retinologists despite almost 30 years of research history. New diagnostic tools, based on the genetic profiles of patients with retinal detachment (RD), are now available. In addition, clinical trials in humans are about to begin of new pharmacological approaches, based on so-called 'biological agents'. Thus, it might be that, in the near future, it will be possible to reduce the incidence of PVR, which currently accounts for 8-10 % of all cases of RD.
Medical Treatments for Proliferative Vitreoretinopathy
When determining the classifications of PVR, much emphasis was put on the appearance of fibrous membranes over the surface of retina and vitreous that further contract, causing a tractional RD with poor prognosis, both anatomical and functional. The original classification also recognised the existence of subretinal membranes in some patients.
At the time of the original classification, retinal pigment epithelial cells (RPE) were identified as having a main role in the development of PVR. Therefore, intravitreal proliferation of fibroblast-like cells was considered a target for the prevention of this severe complication.
As a result, some antiproliferative agents were tested in animal models and in humans, although with disappointing results. Unfortunately, research on PVR is not currently in fashion and retinologists are paying less attention to this complication. This is despite its prevalence remaining unchanged (between 8 and 10 %) and its anatomical and functional results being a 'catastrophe' for the patient.
Given that the prevalence of RD is almost 1.5 new cases per 10,000 inhabitants per year, PVR might affect up to 7,000 patients every year in a country such as Spain (with a population of 44 million people).
Once PVR has appeared, the chances of having multiple surgeries increases for the patient, resulting in escalating costs for the healthcare system, as reported for the National Health Service in the UK in 2004.
Collaborative Studies of Proliferative Vitreoretinopathy
With the aim of providing additional information, two collaborative studies by several centres in Europe (Spain, Portugal, UK and Holland) have been underway since 2004, co-ordinated by the Eye Institute (IOBA) of the University of Valladolid (Spain). These studies, named Retina 1 and Retina 4, have already produced papers and more information is now been processed. These studies DOI: 10.17925/EOR.2011.05.02.139 are contributing greatly to the clarification of previous ideas and concepts relating to PVR.
Revision of Current Proliferative Vitreoretinopathy Classification
These collaborative studies have already shown that existing PVR classifications must be significantly revised. Although several proposals were made during the 1990s, the initial classification is still the most used in publications. However, few clinicians use it in clinical practice because it does not provide useful information, regarding neither the severity of the disease nor the activity of the scarring process. In addition, it does not take into account the existence of intraretinal changes that occur in many patients, adding severity to the situation and forcing surgeons to perform complicated procedures, such as large retinectomies.
Thus, a simpler classification has been proposed based on the existence of three types of PVR: epiretinal (the known membranes over the retina surface), subretinal (rare and frequently associated to previous surgical attempts or post-traumatic RD) and intraretinal (the most severe form).
These three types of PVR can co-exist in some patients. 
Concluding remarks
If RD cannot be avoided, challenges for the near future should be the prophylaxis of its most serious complication, PVR and the restoration of an adequate visual acuity to the patient. However, despite being identified almost 30 years ago, PVR remains a significant clinical problem. n
